Maternal malaria and perinatal HIV transmission, Western Kenya (1,2).
Malaria during pregnancy is a serious problem in sub-Saharan Africa, affecting an estimated 24 million pregnant women; malaria prevalence may exceed 50% among primigravid and secundigravid women in malaria-endemic areas (1). During the past 2 decades, HIV and AIDS have emerged as major problems in many malaria-endemic areas of sub-Saharan Africa, where an estimated 28 million persons are infected with HIV (2). Sub-Saharan Africa accounts for more than two thirds of the world's 40 million HIV-infected persons and 80% of the world's HIV-infected women, with HIV prevalence rates sometimes exceeding 40% among pregnant women (3). Without intervention, as many as 30%-45% of pregnant women infected with HIV will pass the virus to their children through mother-to-child transmission (MTCT) (4), of which 15%-30% is intrauterine or intrapartum.
Given the wide overlap between areas where HIV and malaria are each prevalent, the epidemic of HIV/AIDS in areas where Plasmodium falciparum is endemic has generated concern about potential interactions between the two infections, especially in sub-Saharan Africa (5-9). Studies have shown increased HIV replication both in blood mononuclear cells exposed to malaria antigens in vitro (10) and in transgenic mice infected with P. chabaudi (11). Proviral loads are also higher among HIV-infected persons with clinical malaria compared to those without malaria; these levels remain high for at least 4 weeks after treatment (12). Although malaria may increase viral replication in the short term, the concern that the malaria-associated increase in viral replication may accelerate HIV disease progression has not been proven (13).
Studies among pregnant women in sub-Saharan Africa have provided the first evidence of an important public health problem arising from the interaction of HIV and malaria. HIV infection appears to impair malarial immunity among pregnant women, as pregnant women infected with HIV demonstrate more frequent and higher density parasitemia than pregnant women not infected with HIV (5-7,14). More recent case-control (15) and longitudinal (16,17) studies on the clinical pattern of malaria in HIV-infected, nonpregnant women have shown HIV infection to be associated with an increased frequency of clinical malaria and parasitemia, particularly among persons with advanced HIV disease. Data from Malawi (18) have suggested that infants exposed in utero to both placental malaria and maternal HIV infection have an increased risk for postneonatal death three- to eightfold higher than infants born to mothers with either infection alone. We examined the relationship between placental malaria and perinatal HIV transmission in an area of western Kenya with high prevalence of malaria and HIV infection.
Participants and Methods
This study was conducted at Nyanza Provincial General Hospital (NPGH), a large publicly funded hospital in Kisumu (population 300,000) in western Kenya. Malaria transmission within Kisumu town is perennial, and P. falciparum is the predominant species, accounting for 98% of malaria cases (19). Chloroquine resistance is prevalent in the area: 75%-80% of P. falciparum strains show a RII/RIII resistance pattern (20). The prevalence of HIV infection among pregnant women is approximately 25% (6,21).
Recruitment and Follow-up
Pregnant women were enrolled from June 1996 through May 2000. Screening procedures have been described previously (21). Briefly, women at the antenatal clinic were eligible for participation if they had an uncomplicated singleton pregnancy of [greater than or equal to]32 weeks' gestation (based on the fundal height estimation), resided within the Kisumu municipality, and had no known underlying chronic illness. Following informed consent, a structured questionnaire was administered in the local language (Dholuo or Kiswahili) to obtain information on sociodemographic, health, and obstetric factors.
A trained HIV counselor then counseled each woman, and a posttest counseling appointment was made. A blood sample was taken for HIV antibody testing, hemoglobin level, and malaria thick blood film. All screened women were encouraged to deliver at NPGH. In addition, nonscreened women who delivered at NGPH were eligible for participation if they met study inclusion criteria. Routine use of zidovudine or nevirapine was not the Kenyan Ministry of Health policy during the study period, and these drugs were not available in Ministry of Health facilities.
At delivery, information was collected on mode and outcome of delivery and any illness and treatment in the previous 2 weeks. Within 24 hours of birth, infants were weighed ([+ or -]1 g) on an electronic balance (Ohaus, Florham Park, NJ), and gestational age was assessed by using the Ballard method (22). All live, singleton, vaginally delivered infants of HIV-positive mothers were eligible for study. Infants were seen monthly until 12 months of age.
Informed consent was obtained from all women before they were enrolled in this study. Human subjects guidelines of the Centers for Disease Control and Prevention (CDC) and the Kenya Medical Research Institute ethical review committee were strictly followed. Mothers of enrolled infants signed an additional informed consent form for infant participation.
The study protocol was approved in 1995 by the institutional review boards of the Kenya Medical Research Institute; CDC, Atlanta, Georgia, USA; and the Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands, and was reviewed annually by the participating institutions. This study occurred during a changing environment in preventing perinatal HIV transmission, with results of studies in other countries demonstrating the benefits of short-course AZT use (23,24) or nevirapine use (25) in late pregnancy and perinatally to reduce the risk for MTCT. Similarly, studies of malaria prevention in pregnancy during the study interval were demonstrating the benefit of intermittent antimalarial treatment to prevent maternal anemia and low birth weight (6,26). The participating institutions and the Kenyan Ministry of Health were engaged in discussions about these findings regarding the ethical considerations for this investigation. The study continued with full ethical approvals during these discussions. Investigators and institutions have supported the transition to a system that supports providing intermittent preventive antimalarial therapy during pregnancy, according to the adopted Kenyan national policy. The MTCT prevention program now offers HIV counseling and testing, community education, and antiretroviral drugs to prevent MTCT in the study setting (4).
Blood Sampling and Laboratory Procedures
At delivery, maternal peripheral and placental thick blood films were prepared, stained with 10% Giemsa, and examined under oil immersion for malaria parasites. Placental blood was obtained by cutting into the maternal side of the placenta and placing collected blood on a slide. A thick film was considered negative if 100 microscopic fields showed no parasites. Malaria parasites and leukocytes were counted in the same fields until 300 leukocytes were counted. Parasite densities were estimated by using an assumed count of 8,000 leukocytes/[micro]L blood.
Blood samples were collected into EDTA tubes. At delivery, blood was collected from mothers of enrolled infants to assess viral load, whether syphilis was present, and hemoglobin level. One month postpartum, maternal venous blood was collected to determine counts of CD4-and CD8-positive T-lymphocytes (CD4+ and CD8+). Capillary blood was collected from infants by a heel prick on the day of delivery and then monthly thereafter for HIV testing. Plasma was separated from blood samples and stored at -70[degrees]C.
Infant HIV testing was done by polymerase chain reaction (PCR) of proviral DNA extracted from peripheral blood mononuclear cells (27). HIV testing of pregnant women used two rapid test methods: an initial Serostrip HIV-1/2 (Saliva Diagnostic Systems Pte Ltd, Singapore) and a confirmatory Capillus HIV-1/HIV-2 (Cambridge Diagnostics, Wicklow, Ireland) on all Serostrip-positive samples. Sequential testing of samples using both methods has a high sensitivity and specificity (Richard W. Steketee, pers. comm.). Western blot was performed on discordant samples.
Maternal CD4+ and CD8+ counts were assessed by using commercial, dual-label monoclonal antibodies (Becton-Dickinson Immunocytometry, San Jose, CA) and standard fluorescent-activated cell sorting (FACScan, Becton-Dickinson) analysis following whole-blood lysis (28). Maternal HIV-1 viral load was determined by the Roche Amplicor HIV-1 monitor test version 1.0 (Roche Diagnostics, Indianapolis, IN), with a quantification limit of 400 viral copies per milliliter.
Syphilis antibodies were detected by venereal disease research laboratory (VDRL) slide test (EUROTEX-VDRL, Euromedi equip ltd., West Harrow, UK). Hemoglobin was measured to the nearest 0.1 g/dL using a Hemocue machine (Mission Viejo, CA).
An uncomplicated pregnancy was defined as a pregnancy without the presence of AIDS-defining symptoms, hypertension, preeclampsia, polyhydramnios, abnormal fetal presentation, history of a cesarean section, hemorrhage, or repeated spontaneous abortions (>2). Placental parasitemia was defined as any plasmodial asexual form detected on a thick film. Maternal HIV infection was defined as a positive result on both rapid tests; women not reactive with the initial Serostrip HIV-1/2 test were considered HIV uninfected. Women whose serostatus could not be determined (i.e., those with discordant results on the two rapid tests and an indeterminate status with Western blot) were excluded from analysis. Newborns were classified as normal birth weight if they weighed [less than or equal to]2,500 g, regardless of gestational age, and low birth weight if they weighed <2,500 g. Preterm delivery was defined as occurring at <37 weeks of gestation. Small for gestational age was defined as sex-specific birth weight [less than or equal to]10th percentile for weight-for-gestational-age (29).
Determining Infant HIV Status
An algorithm was developed to describe the perinatal HIV infection status of infants. Infants were classified as having acquired HIV infection perinatally (e.g., in utero or during labor and delivery) if they met the following conditions: 1) died and by the time of death had [greater than or equal to]2 consecutive positive HIV PCR tests, the first of which was at [less than or equal to]4 months of age; 2) were lost to follow-up but had had [greater than or equal to]3 consecutive positive PCR results, the first of which was at [less than or equal to]4 months of age; 3) remained alive with continued and consistent positive PCR results, the first of which was at [less than or equal to]4 months of age. Infants were considered negative for perinatally acquired HIV if they had [greater than or equal to]3 PCR tests performed on them, and all tests were negative, with at least one of the negative tests at [greater than or equal to]4 months of age. Because infants had to be [greater than or equal to]4 months old to be classified as uninfected, those who died or were lost to follow-up before 4 months of age were excluded. Infants who acquired HIV at [greater than or equal to]5 months of age were considered to have acquired HIV postnatally and were included as nontransmitters from the perinatal perspective. Infants for whom we had insufficient PCR data to determine their status were classified as indeterminate and were excluded. Mothers of infected infants were classified as transmitters and those of uninfected infants as nontransmitters.
Data Analysis and Statistical Methods
Plasma virus levels load below the limit of quantification (400 copies/[micro]L) were assigned a value of 200 copies/[micro]L; plasma viral load results were then [log.sub.10]-transformed. We defined high-density placental parasitemia as [greater than or equal to] 10,000 parasites/[micro]L, which corresponded approximately to the uppermost quintile of parasite density. Univariate analyses were performed by using [chi square] or Fisher exact tests (for cross-tabulations with an expected value in any cell [less than or equal to]5) to compare proportions for categorical variables; t tests were used to compare normally distributed continuous variables. Relative risks (RRs) were computed with their 95% confidence interval (CI) to measure the strength of the associations between potential risk factors and perinatal MTCT.
To evaluate the effect of placental malaria on perinatal MTCT, a Poisson log-linear model containing placental malaria and maternal viral load as primary predictor variables was constructed by using backward elimination; adjusted RRs were computed. An interaction term between placental malaria density and maternal viral load was significant (p = 0.02) and was retained in the model. Because women with and without placental malaria may have different risk factors for perinatal MTCT, we fit three separate multivariate models: all study women, women without placental malaria, and women with placental malaria. All tests were two-sided; p values <0.05 were considered significant. Analysis was done using STATA (StataCorp. 2001. Stata Statistical Software: Release 7.0 College Station, TX) and SAS (Version 8.0, SAS Institute, Cary, NC).
A total of 829 mother-infant pairs were enrolled; 317 (38.2%) infants with incomplete follow-up or indeterminate HIV status were excluded, leaving 512 mother-infant pairs. Included and excluded women did not differ in age, level of education, mean maternal viral load, mean CD4+ counts, malaria rates, high-density malaria rates, proportion of low birth order (i.e., gravida [less than or equal to]2 versus [greater than or equal to]3), and rates of episiotomy or perineal tear. However, excluded women were more likely to have infants born with low birth weight (9.1% versus 5.5%, p = 0.04). The baseline characteristics of the 512 women included in the analysis are shown in Table 1. Among these 512 women, 128 (25.0%) had placental malaria and 353 (84.4%) had anemia (hemoglobin <11 g/dL).
Correlates of Perinatal MTCT
Of 512 mothers, 102 (19.9%) transmitted HIV to their infants perinatally. High maternal viral load ([greater than or equal to] 10,000 viral copies/[micro]L) and low CD4+ count (<200 cells/[micro]L) were significantly associated with perinatal MTCT (Table 2). When analyzed as continuous variables, transmitting mothers had higher geometric mean viral loads than nontransmitting mothers (7,083 versus 1,378 copies/[micro]L; p<0.001) and low mean CD4+ count (511 versus 657 cells/[micro]L; p<0.001). Other characteristics significantly associated with perinatal MTCT included episiotomy or perineal tear, low birth weight or small-for-gestational-age infants, and being of low birth order (primigravid or secundigravid).
Maternal peripheral parasitemia at delivery was not associated with MTCT; however, placental malaria was associated with a 40% reduction in the risk for perinatal MTCT (RR 0.6, 95% CI 0.4 to 1.0, p = 0.05) (Table 2). Compared to women without placental malaria (perinatal MTCT rate = 21.9%), women with placental parasitemia at lower densities (<10,000 parasites/[micro]L) had a lower rate of perinatal MTCT (11.5%); this was not true for women with higher-density placental parasitemia ([greater than or equal to] 10,000 parasites/[micro]L, perinatal MTCT rate = 25.0%), who represented approximately one fifth of women with placental malaria. Among women with viral load below the detection level, perinatal MTCT occurred in none of 35 mothers with malaria, compared to 10 (8.7%) of 115 mothers without malaria (p = 0.12).
Multivariate Analysis of Risk Factors for Perinatal MTCT
Among all study women, high maternal viral load and episiotomy or perineal tear were independent risk factors, and low-density (but not high-density) malaria was an independent protective factor for perinatal MTCT. Among women without microscopically detectable placental malaria, high maternal viral load, gravidity [less than or equal to]2, and low birth weight in the newborn were significant risk factors or markers for perinatal MTCT. Among women with placental malaria (where perinatal MTCT was overall lower than in the malaria-negative women), high maternal viral load, episiotomy or perineal tear, and high-density placental infection were significant risk factors for perinatal MTCT (Table 3). In both the multivariate models for the entire population and women with placental malaria, significant interaction was found between viral load and placental malaria density.
In further examination of the interaction between maternal viral load and placental malaria, we found no significant differences in the frequency of episiotomy or perineal tear, mean CD4+ count, mean maternal hemoglobin level, mean birth weight, and frequency of small-for-gestational-age neonates among women without malaria, those with low-density placental malaria, and those with high-density placental malaria. Women with placental malaria were of lower mean gravidity than women without malaria (2.1 vs. 2.4, p = 0.03). Geometric mean maternal viral load was slightly higher in women with low-density placental malaria (2,226 copies/[micro]L) and was nearly twofold higher in women with high-density placental malaria (3,390 copies/[micro]L) than the viral load in women without placental malaria (1,774 copies/[micro]L); however, these differences were not significant (p = 0.14). Viral load was significantly higher among women with peripheral malaria parasitemia at delivery (2,979 copies/[micro]L) than among women without (1,725 copies/[micro]L, p = 0.03). As shown in Table 4, the geometric mean viral load was five-fold higher in transmitters than in nontransmitters. While in women without placental malaria the geometric mean viral load in transmitters was fourfold higher than in nontransmitters, among women with malaria, the geometric mean viral load was 25-fold higher in transmitters than in nontransmitters. Among transmitting women, those with placental malaria had an eightfold higher geometric mean viral load than those women without placental malaria.
These associations were further evaluated in models comparing the relative risk for perinatal transmission between the three groups with placental malaria at various levels of maternal viral load. Low-density placental parasitemia was associated with significant protection for perinatal MTCT at the lower viral load levels, but not at higher viral load levels (Figure 1). When women with low- and high-density parasitemia were compared (Figure 2), high-density placental parasitemia was associated with increased risk for perinatal MTCT but only at the higher viral load levels.
This evaluation of perinatal HIV transmission in a malarious area of western Kenya demonstrated that approximately 20% of infants born to HIV-infected mothers acquired HIV by 4 months of age, similar to rates reported in other sub-Saharan African settings (30-32). Consistent with other studies, we found that maternal viral load in peripheral blood at the time of delivery and having an episiotomy or perineal tear were risk factors for perinatal MTCT (33,34). Contrary to our expectations, we observed that women with placental malaria had lower rates of perinatal MTCT than women without placental malaria. However, women with high-density malaria had significantly higher rates of perinatal MTCT than parasitemic women with low-density malaria. In additional models, only low placental parasite density (1-9,999 parasites/[micro]L of blood) was associated with protection from perinatal MTCT; high-density placental infection was either a risk factor for perinatal MTCT (in the model evaluating only women with malaria) or it was a neutral factor (in the model evaluating all women). Maternal viral load was slightly higher in women with high-density placental malaria, and, among transmitting women, mean viral load was eightfold higher if the woman had concurrent placental malaria, consistent with the suggestion that high-density malaria may be an important stimulus of viral replication (10-12).
Our study had some important limitations. First, only healthy women were screened for this study; no women with AIDS or any known underlying chronic illness were enrolled. Although this eliminated potential conditions that could have complicated the analysis (e.g., a higher likelihood of additional concurrent infections), it restricted our study population to the "healthiest" women with HIV and likely resulted in an underestimate of the overall rate of perinatal MTCT in our study area. Some infants categorized as having acquired HIV through perinatal transmission may have actually acquired it through early breastfeeding transmission. However, including these infants would likely bias the results toward underestimating the magnitude of the observed risks. Our measurement of placental malaria was limited to microscopy examination of placental smears and could have been inexact; those with no evidence of malaria may have had very low-density infection and may have been misclassified as having no malaria. Such misclassification would be expected to bias our findings toward the null hypothesis. Because placental malaria can cause an inflammatory response in the placenta, the use of leukocyte count to calculate parasite density may have resulted in an underestimation. However, our cutoff of 10,000 parasites/[micro]L for high-density placental parasitemia is essentially a relative measure based on the upper quintile of densities; therefore, we do not think that our estimation technique would have introduced any bias. Finally, in a study such as ours, loss to follow-up always has the potential to introduce bias. Approximately one third of infants enrolled in our study were lost to follow-up. However, as noted, these mothers and infants were generally similar to the study population included in our analysis, and we were unable to detect biases that would have affected our analysis.
Our observation of an association between low-density placental malaria and reduced perinatal MTCT has several possible explanations. First, over 16% of women reported self-treatment (typically for fever) with chloroquine during pregnancy. High-grade chloroquine resistance in this area is widespread; its use is unlikely to clear placental infections, but it may reduce parasite densities. Chloroquine is known to have anti-HIV properties and to reduce HIV-1 replication and viral loads in adults (35,36) and as such could potentially reduce the risk for perinatal MTCT. Although we identified no differences in the proportion of women with or without placental malaria who used chloroquine, and no association was found between chloroquine usage and MTCT, women identified as having placental malaria may have used chloroquine more frequently and at higher doses (information that was not collected) than women without placental malaria. A second possibility is that some of the women classified as having placentas negative for malaria parasites may actually have had low-level chronic malaria associated with inflammation and increased HIV replication. In contrast, women classified as having low-density malaria may have had recent malaria with minimal inflammatory response and thus no increase in HIV replication. Unfortunately, blood films are not capable of detecting inflammatory responses.
A more likely explanation is that a balance exists in the uterine-placental-fetal environment among malaria-induced antigen stimulation, HIV viral replication, maternal host immune response to both malaria and HIV, and the likelihood of MTCT. Although high viral load has been shown to increase the risk for MTCT, no more than half of exposed infants, even at high maternal viral load, become infected with HIV-1. These data suggest that other systemic or placental factors must be important in preventing HIV-1 transmission. Recent studies suggest that selected cytokines and hormones potentially affect HIV-1 transplacental transmission and that both innate and acquired protection play a role in MTCT (37). First, malaria is known to induce disequilibrium in the balance between Th1 and Th2 responses, favoring the Th1 pathway (38-40). T-helper responses are known to control HIV replication; hence, inducing Th1 response in the placental compartment could lead to reduced HIV-1 replication (41,42). Indeed, a moderate increase was found in the Th1 cytokine interferon-[gamma] response in the intervillous blood mononuclear cell responses of HIV-positive mothers with placental malaria as compared to HIV-positive mothers without placental malaria (43). Second, leukemia inhibitory factor induces a potent inhibition of HIV replication, and this cytokine is upregulated in placentas of women who do not transmit HIV (44). Malarial antigens may induce production of leukemia inhibitory factor that results in reduced rates of perinatal MTCT. Third, malarial antigen may result in altered chemokine production, which in turn can block chemokine receptors necessary for cellular HIV entry (45). Recent immunologic studies conducted in a group of women who participated in this cohort showed that macrophage inflammatory protein (MIP)- 1[beta], a chemokine known to block the entry of HIV-1, was significantly elevated in the intervillous blood plasma of women with placental malaria irrespective of their HIV status. In women with concurrent HIV and placental malaria, the intervillous blood plasma levels of MIP-1[beta] were significantly elevated compared to HIV-negative women with placental malaria and HIV-positive women without placental malaria (46). Thus, a complex balance of antigen stimulus and immune response may occur in the placenta, as demonstrated in recent studies focusing on the placental intervillous blood responses (38-40,43,46). In this scenario, active placental malaria might lead to one of the local immune responses described. This response may control the density of parasitemia and may also provide immune control that limits perinatal MTCT. For most women with placental malaria (approximately 80% in our study), this resultant balance leads to "protection" with controlled (low-density) malaria and reduced perinatal MTCT. For a minority of women with malaria (approximately 20% in our study), the balance is tilted to inadequate control of placental malaria (i.e., higher density of malaria parasites with concomitant increased antigen stimulation of viral replication and higher viral load) and higher rates of perinatal MTCT. This finding is consistent with our observation that women with high-density placental malaria do have higher rates of perinatal MTCT than women with low-density placental malaria, but that they require much higher viral loads to achieve this transmission. Our findings suggest complex relationships between malaria, viral load, and perinatal MTCT. These findings will need to be confirmed and expanded upon in further research in different settings.
The finding of reduced perinatal MTCT in the presence of low-density, but not high-density, placental malaria does not suggest altering existing recommendations for the use of intermittent preventive antimalarial treatment in pregnant women in malarious areas of Africa (47). For most dually (malaria and HIV) infected women, the overall outcome would have modest benefit in reducing perinatal MTCT, but for the minority with insufficiently controlled infections, perinatal MTCT would be increased. At this point, we cannot differentiate in advance which women will end up in which group. The important benefit of anti-malarial treatment may be to reduce the likelihood of women having high-density placental malaria and in also helping reduce the other known adverse effects of malaria during pregnancy, including anemia, low birth weight, and prematurity (1).
As noted earlier, this study was carried out in Kenya in a changing environment of perinatal HIV and malaria prevention and has been transformed into a program delivering short-course antenatal antiretroviral therapy to HIV-infected women and a system to support providing intermittent preventive antimalarial treatment during pregnancy according to the newly adopted national policy (48). As more countries adopt policies of antiretroviral and antimalarial interventions in pregnancy, the interrelationship and ultimate benefit of these two interventions need to continue to be evaluated.
We thank the project staff at the antenatal clinic, labor ward, counselors, laboratory technicians, and computer data entry staff for assisting in many ways to realize this work. We thank Kevin DeCock, Laurence Slutsker, and Venkatachalam Udhayakumar for their valuable comments on the manuscript; John Odondi, the medical superintendent, and health workers from the Nyanza Provincial General Hospital for their cooperation in the study; the Director of the Kenya Medical Research Institute for his permission to publish this work; and all the pregnant women and their infants for their participation in this study.
This study was supported by grant number AOT0483-PH1-2171, HRN-A-00-04-00010-02 from the United States Agency for International Development and by The Netherlands Foundation for the Advancement of Tropical Research, The Hague, The Netherlands.
(1) This work was presented in part at the Epidemic Intelligence Service Conference, Centers for Disease Control and Prevention, April 2001, Atlanta, GA.
(2) Use of trade names is for identification only and does not imply endorsement by the Kenya Medical Research Institute or The Ministry of Health, Kenya, or by the Public Health Service, U.S. Department of Health and Human Services.
Table 1. Characteristics of HIV-positive women and their newborns participating in perinatal HIV transmission study, Kisumu, western Kenya, 1996-2001 (a) Characteristic All women (N = 512) (b) Maternal sociodemographic Luo ethnicity 87% Mean age (y) [+ or -] SD 22.4 [+ or -] 4.4 (range 14-39) Mean gravidity [+ or -] SD 2.3 [+ or -] 1.4 (range 1-9) Primigravid 35.9% Completed primary education 68.0% (n = 510) ([greater than or equal to] 8 y) No salaried employment 74.3% Married 78.4% History of fever and treatment for malaria History of fever previous week 23.2% (n = 509) at screening History of fever a fortnight 28.0% (n = 511) before delivery Treated with antimalarials in 30.9% current pregnancy Treated with chloroquine during 16.6% current pregnancy Axillary temperature [greater 2.9% (n = 455) than or equal to] 37.5[degrees]C at screening Laboratory VDRL-positive 7.3% (n = 385) Hemoglobin <11 g/dL at screening 84.4% (n = 418) Hemoglobin <8 g/dL at screening 20.6% (n = 418) Mean maternal CD4+ count (% <200 629 [+ or -] 334 (4.7%) cells/[micro]L) 1 mo postpartum (n = 464) Mean maternal [log.sub.10] viral 3.28 [+ or -] 0.92 (33.0%) load at delivery (% below (n = 455) detection limit of 400 copies) Peripheral parasitemia at screening 21.9% (n = 415) Peripheral parasitemia at delivery 19.7% (n = 497) Placental malaria 25.0% Delivery Episiotomy or perineal tear 36.4% Mean duration of rupture of 2.7 [+ or -] 6.2 (15.4%) membranes [+ or -] SD (% >4 hours) Newborn Mean birth weight (% low birth 3144 [+ or -] 420 (5.5%) weight) Prematurity (<37 wks completed 8.2% gestation) Maternal HIV transmitters 102 (19.9%) (a) VDRL, venereal disease research laboratory slide test. (b) If characteristic not measured for all 512 women, n is given in parentheses. Table 2. Risk factors associated with perinatal HIV infection by maternal viral, immunologic, obstetric, and other factors (univariate analysis), western Kenya, 1996-2001 No. infected Variable No. studied (%) Viral load >10,000 No 358 50 (14.0) Yes 97 40 (41.2) CD4+ cells <200 No 442 74 (16.7) Yes 22 13 (59.1) Hemoglobin <8 g/dL at screening No 332 58 (17.5) Yes 86 22 (25.6) 3rd-trimester maternal parasitemia No 324 64 (19.8) Yes 91 15 (16.5) Maternal parasitemia at delivery No 399 83 (20.8) Yes 98 15 (15.3) Placental malaria No 384 84 (21.9) Yes 128 18 (14.1) Ever been treated for tuberculosis No 496 98 (19.8) Yes 13 4 (30.8) Treated with chloroquine during pregnancy No 427 88 (20.6) Yes 85 14 (16.5) Treated for vaginal discharge No 477 93 (19.5) Yes 32 9 (28.1) Hospitalized during current pregnancy No 472 95 (20.1) Yes 39 7 (18.0) History of fever 2 wks before delivery No 368 70 (19.0) Yes 143 32 (22.4) Episiotomy or perineal tear No 325 56 (17.2) Yes 186 46 (24.7) Primi- or secundigravid No 190 26 (13.7) Yes 322 76 (23.6) Low birth weight No 484 91 (18.8) Yes 28 11 (39.3) Prematurity No 468 92 (19.7) Yes 42 10 (23.8) Small for gestational age No 444 83 (18.7) Yes 66 19 (28.8) Relative risk (95% confidence Variable interval) p Viral load >10,000 No Yes 3.0 (2.1 to 4.2) <0.001 CD4+ cells <200 No Yes 3.5 (2.4 to 5.3) <0.001 Hemoglobin <8 g/dL at screening No Yes 1.5 (1.0 to 2.3) 0.09 3rd-trimester maternal parasitemia No Yes 0.8 (0.5 to 1.4) 0.48 Maternal parasitemia at delivery No Yes 0.7 (0.4 to 1.2) 0.22 Placental malaria No Yes 0.6 (0.4 to 1.0) 0.05 Ever been treated for tuberculosis No Yes 1.6 (0.7 to 3.6) 0.33 Treated with chloroquine during pregnancy No Yes 0.8 (0.5 to 1.3) 0.38 Treated for vaginal discharge No Yes 1.7 (0.8 to 2.6) 0.24 Hospitalized during current pregnancy No Yes 0.9 (0.4 to 1.8) 0.74 History of fever 2 wks before delivery No Yes 1.2 (0.8 to 1.7) 0.39 Episiotomy or perineal tear No Yes 1.4 (1.0 to 2.0) 0.04 Primi- or secundigravid No Yes 1.7 (1.1 to 2.5) 0.007 Low birth weight No Yes 2.1 (1.3 to 3.4) 0.008 Prematurity No Yes 1.2 (0.7 to 2.1) 0.52 Small for gestational age No Yes 1.5 (1.0 to 2.4) 0.06 Table 3. Multivariate analysis of risk factors for perinatal HIV transmission, western Kenya, 1996-2001 Adjusted relative risks (ARR) for perinatal HIV transmission (a) All women, (b) N = 454 ARR (95% CI) p [Log.sub.10] viral load 1.8 (1.6 to 2.1) <0.001 Episiotomy or perineal tear 1.6 (1.2 to 2.1) 0.004 Low birth weight -- Gravidity <3 versus [greater than or -- equal to]3 Placental malaria status Negative Reference (c) <10,000 parasites/[micro]L 0.4 (0.2 to 0.6) (b) <0.001 [greater than or equal to] 10,000 0.7 (0.3 to 21.5) (b) NS parasites/[micro]L Adjusted relative risks (ARR) for perinatal HIV transmission (a) Placental malaria-negative, n = 348 ARR (95% CI) p [Log.sub.10] viral load 1.7 (1.4 to 2.0) <0.001 Episiotomy or perineal tear -- Low birth weight 1.9 (1.1 to 3.2) 0.03 Gravidity <3 versus [greater than or 1.8 (1.2 to 2.8) 0.003 equal to]3 Placental malaria status Negative N/A <10,000 parasites/[micro]L N/A [greater than or equal to] 10,000 N/A parasites/[micro]L Adjusted relative risks (ARR) for perinatal HIV transmission (a) Placental malaria- positive, (b) n = 107 ARR (95% CI) p [Log.sub.10] viral load 3.5 (2.5 to 4.8) <0.001 Episiotomy or perineal tear 4.8 (2.3 to 9.7) <0.001 Low birth weight -- Gravidity <3 versus [greater than or -- equal to]3 Placental malaria status Negative <10,000 parasites/[micro]L Reference [greater than or equal to] 10,000 2.0 (1.1 to 3.9) 0.04 parasites/[micro]L (a)-, factor was not returned in the final model; CI, confidence interval; N/A, not applicable; NS, not significant. (b) A significant interaction was found between viral load and placental malaria density (p = 0.02) in these analyses. The effect of this interaction on the relative risk for placental malaria is shown in Figures 1 and 2. All relative risks given in this table do not include this interaction but give a weighted average of the malaria effect placental at various levels of vital load. (c ) An alternative model, in which placental malaria was fit as a binary variable (positive or negative), showed that placental malaria was protective for perinatal HIV transmission (relative risk 0.4, 95% CI 0.3 to 0.7, p < 0.001). In that model, [log.sub.10], viral load and episiotomy or perineal tear remain independent risk factors. Table 4. Association between maternal viral load and placental malaria among women who did and did not transmit HIV perinatally to their infants, western Kenya, 1996-2001 Geometric mean HIV viral load (a) p value Transmitters Nontransmitters (b) All women (N = 455) 7,083 1,378 <0.001 Placental malaria-positive 41,217 1,675 <0.001 Placental malaria-negative 5,402 1,286 <0.001 p value 0.002 0.26 (a) Viral load expressed as copies per microliter of plasma. (b) p from t test.
(1.) Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001;64(1-2 Suppl):28-35.
(2.) Global HIV/AIDS epidemic update. Geneva: UNAIDS/World Health Organization; 2001.
(3.) De Cock KM, Weiss HA. The global epidemiology of HIV/AIDS. Trop Med Int Health 2000;5:A3-A9.
(4.) De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000;283:1175-82.
(5.) Steketee RW, Wirima JJ, Bloland PB, Chilima B, Mermin JH, Chitsulo L, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996;55:42-9.
(6.) Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998;59:813-22.
(7.) Verhoeff FH, Brabin BJ, Hart CA, Chimsuku L, Kazembe P, Broadhead RL. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health 1999;4:5-12.
(8.) Chandramohan D, Greenwood BM. Is there an interaction between human immunodeficiency virus and Plasmodium falciparum? Int J Epidemiol 1998;27:296-301.
(9.) French N, Gilks CF. Royal Society of Tropical Medicine and Hygiene meeting at Manson House, London, 18 March 1999. Fresh from the field: some controversies in tropical medicine and hygiene. HIV and malaria, do they interact? Trans R Soc Trop Med Hyg 2000;94:233-7.
(10.) Xiao L, Owen SM, Rudolph DL, Lal RB, Lal AA. Plasmodium falciparum antigen-induced human immunodeficiency virus type 1 replication is mediated through induction of tumor necrosis factor-alpha. J Infect Dis 1998;177:437-45.
(11.) Freitag C, Chougnet C, Schito M, Near KA, Shearer GM, Li C, et al. Malaria infection induces virus expression in human immunodeficiency virus transganic mice by CD4 T cell-dependent immune activation. J Infect Dis 2001;183:1260-8.
(12.). Hoffman IF, Jere CS, Taylor TE, Munthali P, Dyer JR, Wirima JJ, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999;13:487-94.
(13.) Greenberg AE, Nsa W, Ryder RW, Medi M, Nzeza M, Kitadi N, et al. Plasmodium falciparum malaria mid perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children. N Engl J Med 1991;325:105-9.
(14.) van Eijk AM, Ayisi JG, ter Kuile FO, Misore A, Otieno JA, Kolczak MS, et al. Human immunodeficiency virus seropositivity and malaria as risk factors for third-trimester anemia in asymptomatic pregnant women in western Kenya. Am J Trop Med Hyg 2001;65:623-30.
(15.) Francesconi P, Fabiani M, Dante MG, Lukwiya M, Okwey R, Ouma J, et al. HIV, malaria parasites, and acute febrile episodes in Ugandan patients: a case-control study. AIDS 2001; 15:2445-50.
(16.) Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000;356:1051-6.
(17.) French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001;15:899-906.
(18.) Bloland PB, Wirima JJ, Steketee RW, Chilima B, Hightower A, Breman JG. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS 1995;9:721-5.
(19.) Spencer HC, Kaseje DC, Collins WE, Shehata MG, Turner A, Stanfill PS, et al. Community-based malaria control in Saradidi, Kenya: description of the programme and impact on parasitaemia rates and antimalarial antibodies. Ann Trop Med Parasitol 1987;81:13-23.
(20.) Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993;167:932-7.
(21.) Ayisi JG, van Eijk AM, ter Kuile FO, Kolczak MS, Otieno JA, Misore AO, et al. Risk factors for HIV infection among asymptomatic pregnant women attending an antenatal clinic in western Kenya. Int J STD AIDS 2000;11:393-401.
(22.) Ballard JL, Novak KK, Driver M. A simplified score for assessment of fetal maturation of newly born infants. J Pediatr 1979;95:769-74.
(23.) Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353:773-80.
(24.) Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999;353:781-5.
(25.) Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999;354:803-9.
(26.) Wolfe EB, Parise ME, Haddix AC, Nahlen BL, Ayisi JG, Misore A, et al. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. Am J Trop Med Hyg 2001;64:178-86.
(27.) Yang C, Dash BC, Simon F, van der Groen G, Pieniazek D, Gao F, et al. Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis 2000;181:1791-5.
(28.) Centers for Disease Control and Prevention. 1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR Morb Mortal Wkly Rep 1997;46:1-29.
(29.) Williams RL, Creasy RK, Cunningham GC, Hawes WE, Norris FD, Tashiro M. Fetal growth and perinatal viability in California. Obstet Gynecol 1982;59:624-32.
(30.) Bulterys M, Chao A, Dushimimana A, Habimana P, Nawrocki P, Kurawige JB, et al. Multiple sexual partners and mother-to-child transmission of HIV-1. AIDS 1993;7:1639-45.
(31.) Bertolli J, St Louis ME, Simonds RJ, Nieburg P, Kamenga M, Brown C, et al. Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J Infect Dis 1996;174:722-6.
(32.) Wabwire-Mangen F, Gray RH, Mmiro FA, Ndugwa C, Abramowsky C, Wabinga H, et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquit Immune Defic Syndr 1999;22:379-85.
(33.) Mandelbrot L, Burgard M, Teglas JP, Benifla JL, Khan C, Blot P, et al. Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999;13:2143-9.
(34.) Risk factors for mother-to-child transmission of HIV-1. European Collaborative Study. Lancet 1992;339:1007-12.
(35.) Savarino A, Gennero L, Chert HC, Serrano D, Malavasi F, Boelaert JR, et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 2001;15:2221-9.
(36.) Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. J Clin Virol 2001;20:131-5.
(37.) Bulterys M, Nolan ML, Janieson DJ, Dominguez K, Fowler MG. Advances in the prevention of mother-to-child HIV-1 transmission: current issues, future challenges. AIDScience [serial on the Internet] 2002 Feb. Available from: http://aidscience.org/Articles/aidscience017.asp
(38.) Fried M, Muga RO, Misore AO, Duffy PE. Malaria elicits type 1 cytokines in the human placenta: IFN-gamma and TNF-alpha associated with pregnancy outcomes. J Immunol 1998;160:2523-30.
(39.) Moore JM, Nahlen BL, Misore A, Lal AA, Udhayakumar V. Immunity to placental malaria. I. Elevated production of interferon-[gamma] by placental blood mononuclear cells is associated with protection in an area with high transmission of malaria. J Infect Dis 1999;179:1218-25.
(40.) Chaisavanceyakorn S, Moore JM, Otieno J, Chaiyaroj SC, Perkins DJ, Shi YP, et al. Immunity to placental malaria. III. Impairment of interleukin (IL)-12, not IL-18, and interferon-inducible protein-10 responses in the placental intervillous blood of human immunodeficiency virus/malaria-coinfected women. J Infect Dis 2002;185:127-31.
(41). Seder RA, Grabstein KH, Berzofsky JA, McDyer JF. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med 1995;182:1067-77.
(42.) Gandhi RT, Walker BD. Immunologic control of HIV-I. Annu Rev Med 2002;53:149-72.
(43.) Moore JM, Ayisi J, Nahlen BL, Misore A, Lal AA, Udhayakumar V. Immunity to placental malaria. II. Placental antigen-specific cytokine responses are impaired in human immunodeficiency virus-infected women. J Infect Dis 2000;182:960-4.
(44.) Patterson BK, Behbahani H, Kabat WJ, Sullivan Y, O'Gorman MR, Landay A, et al. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J Clin Invest 2001;107:287-94.
(45.) Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
(46.) Chaisavaneeyakorn S, Moore JM, Mirel L, Othoro C, Otieno J, Chaiyaroj SC, et al Levels of macrophage inflammatory protein 1 alpha (MIP-1 alpha) and MIP-1 beta in intervillous blood plasma samples from women with placental malaria and human immunodeficiency virus infection. Clin Diagn Lab Immunol 2003;10:631-6.
(47.) WHO expert committee on malaria, twentieth report. Geneva: World Health Organization; 2000.
(48.) van't Hoog AH, Otieno JA, Mature L, Obare-Okeyo R, Taren D, Misore A, et al. Low uptake of services in a pilot prevention of mother to child HIV transmission (PMCT) program in Kisumu, Western Kenya. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona, Spain. Abstract no. MoOrF1033.
Dr. Ayisi is a senior research officer at the Centre for Vector Biology and Control Research, Kenya Medical Research Institute, Kisumu. His research interests include the epidemiology and control of malaria in pregnancy.
Address for correspondence: Robert D. Newman, Malaria Branch, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop F22, Atlanta, GA 30341, USA; fax: 770-488-4206; email: email@example.com
John G. Ayisi, * ([dagger]) Anna M. van Eijk,* ([dagger]) Robert D. Newman, ([double dagger]) Feiko O. ter Kuile, * ([dagger]) ([double dagger]) Ya Ping Shi, * ([double dagger]) Chunfu Yang, ([double dagger]) Margarette S. Kolczak, ([double dagger]) Juliana A. Otieno, ([section]) Ambrose O. Misore, ([section]) Piet A. Kager, ([dagger]) Renu B. Lal, ([double dagger]) Richard W. Steketee, ([double dagger]) and Bernard L. Nahlen ([double dagger]) ([paragraph])
* Centre for Vector Biology and Control Research, Kenya Medical Research Institute, Kisumu, Kenya; ([dagger]) University of Amsterdam, Amsterdam, The Netherlands; ([double dagger]) Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ([section]) Ministry of Health, Kisumu, Kenya; and ([paragraph]) World Health Organization, Geneva, Switzerland
|Printer friendly Cite/link Email Feedback|
|Author:||Nahlen, Bernard L.|
|Publication:||Emerging Infectious Diseases|
|Date:||Apr 1, 2004|
|Previous Article:||Coccidioidomycosis among workers at an archeological site, Northeastern Utah.|
|Next Article:||Ixodid and argasid tick species and West Nile virus.|